Conclusion and proposal of the Homeopathic Medicinal Products Working Group (HMPWG) in answer to the comments submitted by the stakeholders during the public consultation.

The first list of justified stocks is a non-exhaustive list of well known stocks, whose homeopathic use is considered satisfactorily justified in accordance with the requirements laid down in “Points to consider on the Justification of homeopathic use of the stock-HMPWG June 2012” (relevant bibliography on human use, more specifically, materia medica and provings).

The references were extracted from the broader commercially available electronic data base. This extraction of the bibliographical references, based on the name of the stocks, has been prepared by a Belgian expert, a member of the Belgian commission for homeopathic medicinal products for human and veterinary use, who is supported by homeopathic prescribers associations. For this extraction which was offered in 2010 to the HMPWG members, only the available literature in the English language has been selected.

For each stock listed, the homeopathic literature and the description of the stocks in the official pharmacopoeias have been verified.

During assessment where differences in the description of the stocks were identified, the subgroup of the HMPWG assessed and concluded to either
   - maintain the stocks in the list where differences were considered insignificant, or
   - to temporarily remove the stocks from the list where there were significant differences, until they could be further evaluated

In order to increase harmonization in the future, it is intended to inform the pharmacopoeial authorities of differences identified, taking into account the homeopathic literature available.
For all stocks where a European Pharmacopoeial (Ph. Eur.) monograph exists, only this mandatory reference has been selected.

This first list is non exhaustive and is based on a consensus between all members of the HMPWG. It may be considered that subsequent lists will also be non-exhaustive.

The goal was to compile, as soon as possible, a list of stocks to which the stakeholders could refer to in their submissions.
Please note that
   - the mention of a Pharmacopoeial reference in the list is to ensure an official definition for each stock; it is not a sufficient way to justify homeopathic use;
- where a monograph exists in the Ph. Eur. for a ‘homeopathic stock”, reference to this monograph is considered mandatory unless otherwise justified;

- the edition of the Pharmacopeia has not been specified (see general practice ) in order to systematically refer to the current version in force;

- if a stock is under further (ongoing) assessment it will not impact the ongoing or already existing national decisions and procedures.

The HMPWG has decided to further evaluate the stock Arnica prepared from dried underground parts. This is because the raw material is not the same as that quoted in the majority of the references related to the homeopathic use described previously and requires a more developed assessment report including an assessment of the comparative description of symptoms and discussion on a harmonized European denomination/labeling).

The priority of the HMPWG is to finalize and publish the most comprehensive list possible. In addition the strategy is also to ensure that those stocks which require further assessment do not create unnecessary delays in the publication of a first list.

The HMPWG acknowledge the interest of some stakeholders in contributing to the development of this list and in order to support and accelerate the work of the HMPWG, if they consider it useful, they are invited to:

- comment on any differences between the use of fresh and dried raw materials submitting relevant bibliographical references if available;

- submit a proposal to the HMPWG for a ‘next list’, with a compilation of corresponding data, which conforms with the requirements of the PTC and establishes the link between the homeopathic literature and the description of the stock
  o as described in official pharmacopoeia(s)
  o not described in an official pharmacopoeia;

- contribute to stocks still under assessment by the HMPWG (e.g. Berberis vulgaris, Bryonia, Cactus grandiflorus, Phytolacca, Pulsatilla vulgaris, Rhus tox, Sambucus nigra, Solanum dulcamara, Thuya and Viscum album, ).